Sponsor of the Day:
Jerkmate
https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-17-11-00-00-3239014
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically...
Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the...
press release sanofiphase 2bmaintenance datademonstratedclinically
https://www.merck.com/news/merck-announces-initiation-of-pivotal-phase-2b-3-trial-evaluating-mk-8748-tiespectus-an-investigational-bispecific-tie2-agonist-vegf-inhibitor-for-the-treatment-of-neovascular-age-related-macular/
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an...
Apr 6, 2026 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also...
announces initiationpivotal phase2b 3trial evaluatingmerck
https://www.psychiatrist.com/jcp/a-phase-2b-multicenter-study-to-evaluate-basmisanil-as-an-adjunctive-treatment-in-patients-with-cognitive-impairment-associated-with-schizophrenia/
A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With...
Apr 14, 2026 - Although basmisanil did not improve cognitive deficits, the results offer insight into factors that should facilitate design of more informative trials.
phase 2bmulticenter studyevaluatetreatmentpatients